EUCTR2009-009039-32-SE进行中（未招募）不适用
Abciximab versus Eptifibatide versus Bivalirudin during PCI in patients with acute coronary syndromes
Sahlgrenska University Hospital0 个研究点开始时间: 2009年2月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age over 18 years.
- •2.Patients with STEMI, treated with primary PCI or patients with NSTEMI treated with PCI.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Intolerance to abciximab, eptifibatide, tirofiban, ASA eller clopidogrel.
- •Increased risk for bleedings
- •Patients with prior hemmoragic stroke
- •Patients with ischemic stroke the last 6 months
- •Patients with gastrointestinal or genitourinary bleeding the last two months
- •Patients with ongoing warfarin or oral thrombin inhibitor treatment
- •Patients treated recently with thrombolysis (rescue PCI)
- •History of Heparin induced trombocytopenia (HIT)
- •Known platelet count =100.000 per deciliter
- •Known hemoglobin level = 10mg per deciliter
- •Known renal failure with serum creatinine levels over 200 µmol/L
- •History of prior myocardial infarction
- •History of medically treated angina pectoris
- •History of prior PCI or CABG
- •Patients presenting with cardiogenic shock
- •Presence of systemic disease with a less than a year expected life duration
- •Patient`s unweeling in participating in the study
- •Difficulties in communication between the medical stuff and the patient, even due to language problems or due to the patients` disease status
研究者
相似试验
进行中（未招募）
不适用
Eptifibatide Versus Abciximab in primary PCI for Acute ST elevation Myocardial Infarction (EVA-AMI) - EVA-AMIPrimary percutaneous coronary intervention (PCI) for ST-elevation Myocardial Infarction (STEMI)MedDRA version: 8.1Level: LLTClassification code 10028596Term: Myocardial infarctionEUCTR2006-002407-14-DEGlaxoSmithKline Research, European Medical Governance400
已完成
3 期
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)Infarction, MyocardialNCT00426751GlaxoSmithKline429
招募中
3 期
Combination of baricitinib and anti-TNF in rheumatoid arthritis2024-511442-39-00Centre Hospitalier Universitaire De Bordeaux169
进行中（未招募）
1 期
iraparib versus niraparib-bevacizumab combination in Women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancerMedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004269-26-SEordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)94
进行中（未招募）
1 期
iraparib alone or Niraparib and bevacizumab combination in Women with ovarian cancer.Women with relapsed platinum-sensitive epithelial ovarian cancerMedDRA version: 20.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061344Term: Peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004269-26-DKordic Society of Gynaecological Oncology - Clinical Trial Unit110